Group 1 - Immunocore Holdings PLC (IMCR) closed at $29.06, with a 2.3% gain over the past four weeks, and has a mean price target of $62.29, indicating an upside potential of 114.4% [1] - The average of 14 short-term price targets ranges from a low of $24 to a high of $100, with a standard deviation of $23.44, suggesting variability in analyst estimates [2] - Analysts show strong agreement on the company's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 42.9% over the last 30 days, with seven estimates moving higher and no negative revisions [12] - IMCR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement [13]

Core Viewpoint - Seres Therapeutics (MCRB) shows significant upside potential with a mean price target of $60.25, indicating a 713.1% increase from its current price of $7.41 [1] Price Targets and Analyst Consensus - The average price target for MCRB ranges from a low of $6 to a high of $200, with a standard deviation of $93.35, indicating high variability among analysts [2] - The lowest estimate suggests a 19% decline from the current price, while the highest estimate indicates a potential upside of 2599.1% [2] - A tight clustering of price targets, represented by a low standard deviation, suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts have shown strong agreement in revising MCRB's earnings estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 80.3%, with three estimates moving higher and no negative revisions [12] - MCRB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Group 1 - Zoetis (ZTS) closed at $160.35, with a 7.9% gain over the past four weeks, and a mean price target of $202.33 indicating a 26.2% upside potential [1] - The average of 15 short-term price targets ranges from a low of $165 to a high of $244, with a standard deviation of $23.91, suggesting variability in analyst estimates [2] - Analysts show strong agreement on ZTS's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for ZTS has increased by 2.9% due to eight upward revisions and one downward revision in earnings estimates over the last 30 days [12] - ZTS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While price targets should not be the sole basis for investment decisions, the direction implied by them can serve as a useful guide [10][13]

Core Viewpoint - Backblaze, Inc. (BLZE) shares have increased by 13.4% in the past four weeks, closing at $5.32, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $10.83, representing a 103.6% upside [1] Price Targets - The average price targets from analysts range from a low of $8 to a high of $14, with a standard deviation of $1.94, indicating variability in estimates; the lowest estimate suggests a 50.4% increase, while the highest points to a 163.2% upside [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates - Analysts have shown increasing optimism about BLZE's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 3.3% over the past month, with four estimates increasing and no negative revisions [12] Zacks Rank - BLZE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside in the near term [13]

Core Viewpoint - Stoke Therapeutics, Inc. (STOK) has shown a significant price increase of 25.2% over the past four weeks, with a mean price target of $22.38 indicating a potential upside of 132.4% from the current price of $9.63 [1] Price Targets and Analyst Consensus - The average price target for STOK ranges from a low of $15 to a high of $35, with a standard deviation of $6.82, suggesting variability in analyst estimates [2] - The lowest estimate indicates a potential increase of 55.8%, while the most optimistic estimate points to a 263.5% upside [2] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts have shown strong agreement in revising STOK's earnings estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has increased by 59.1% over the past month, with three estimates going higher and no negative revisions [12] - STOK holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

SkyWater Technology, Inc. (SKYT) closed the last trading session at $8.15, gaining 23.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $11 indicates a 35% upside potential.The average comprises five short-term price targets ranging from a low of $8 to a high of $12, with a standard deviation of $1.73. While the lowest estimate indicates a decline of 1.8% from the current price le ...

Palo Alto Networks, Inc. (PANW) is scheduled to report its third-quarter fiscal 2025 results on May 20.Palo Alto Networks projects its fiscal third-quarter revenues in the range of $2.26-$2.29 billion, which suggests a year-over-year increase of 14-15%. The Zacks Consensus Estimate is pegged at $2.27 billion, which implies growth of 14.6% from the year-ago reported figure.After a two-for-one stock split of PANW stocks on Nov. 20, 2024, the consensus mark for PANW’s fiscal third-quarter non-GAAP earnings has ...

ATLANTA, May 16, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Iovance’s business, operations, and prospects, including allegations that: (1) new Authorized Treatment Centers (“ATCs”) were experiencing longer timelines to begin treating patients with A ...

Alexander Spatari | Moment | Getty Imageswatch nowThe change away from traditional user inputs and to agentic AI is significant, according to Jay Richmond, senior director at travel consultant Amadeus. "Today, travel companies provide us with trip recommendations based on search parameters we specify, like date and budget, as well as our browsing and purchase history to present a large range of options. Personalization exists but is limited by a significant lack of context, and context is everything when it ...

I’m bullish on Atlassian (NASDAQ: TEAM ) and I think it’s a stock that’s being wildly misunderstood right now. It’s trading at $225 way off its 52-week high of $326.00 which screams opportunity to me. This is a company that has essentiallyWith over 15 years of experience in the markets and a degree in economics, I focus on breaking down companies with clarity and discipline. My goal is to give individual investors a straightforward, honest view—what’s working, what isn’t, and where the risks and opportuniti ...